

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-628

C# M#

HALE et al

Group Art Unit:


Serial No. 09/998,923

Examiner:

Filed: December 3, 2001

Date: August 14, 2002

Title: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

Assistant Commissioner for Patents  
Washington, DC 20231IDS/#5  
8.16.02  
**RECEIVED**  
AUG 15 2002  
TECH CENTER 1600/2900

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment **e** minus highest number  
previously paid for **20** (at least 20) = **0** x \$ 18.00 \$ 0.00

Independent claims after amendment **0** minus highest number  
previously paid for **3** (at least 3) = **0** x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered , filed

☐ Submission attached

**Subtotal \$ 0.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:tat

NIXON & VANDERHYE P.C.  
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

HALE et al

Atty. Ref.: 1579-628

Serial No.: 09/998,923

Group Art Unit:

Filed: December 3, 2001

Examiner:

For: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

\* \* \* \* \*

August 14, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

**RECEIVED**

AUG 15 2002

TECH CENTER 1600/2900

Each enclosed document listed on the herewith Form PTO-1449 was cited in the attached International Search Report, dated August 2, 2002, issued in a counterpart International application not more than three months ago.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith Form PTO-1449 with the



HALE et al -- Serial No.: 09/998,923

Examiner's initials in the left column per MPEP 609 are earnestly solicited.

Respectfully submitted,

**NIXON & VANDERHYE, P.C.**

By Mary J. Wilson  
Mary J. Wilson  
Reg. No. 32,955

MJW:tat

1100 North Glebe Road  
8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

